Back to News
Market Impact: 0.22
Novavax's XFG-Adapted Nuvaxovid Approved In U.S., EU, Japan For 2026-2027 Season
Source: Nasdaq
Pandemic & Health EventsRegulation & LegislationCompany Fundamentals
Novavax said Sanofi and Takeda received regulatory approvals for the XFG-adapted Nuvaxovid COVID-19 vaccine for the 2026–2027 season across major markets, including the U.S., EU, and Japan. The approvals improve visibility on future demand, though no financial terms or guidance were provided in the update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
NVAX0.60
SNY0.20
More News
- ‘If nothing is done, it’s almost inevitable’: Ukraine’s Yuriy Ryzhenkov on why steelmaking is on the brink of collapse as Russian bombing intensifies
- Why is LG Innotek stock plunging today?
- TotalEnergies, KKR expand U.S. solar venture with 700 MW addition
- TSMC expected to report sixth straight quarter of record profit thanks to AI boom
- Vår Energi cuts 2026 output forecast; Q3 production at 369,000 boepd
- CXMT: How big is its market threat to Samsung, SK Hynix and Micron?